KUALA LUMPUR – TOPVISION Eye Specialist Berhad (“TOPVISION” or the “Company”), an experienced player in medical eye care services in Malaysia, is pleased to announce that its Public Offering for the Malaysian public has been oversubscribed by 58.69 times. This overwhelming response reflects strong investor confidence in TOPVISION’s strategic plans and growth potential.
TOPVISION’s Public Offering entails a public issue of 54.22 million new ordinary shares (“Issue Shares”) in conjunction with the transfer of its listing from the LEAP Market to the ACE Market of Bursa Malaysia Securities Berhad (“Bursa Securities”). The Public Offering comprises:
- 15.49 million Issue Shares allocated for application by the Malaysian public through balloting, evenly split between Bumiputera and non-Bumiputera investors;
- 4.80 million Issue Shares designated for eligible directors, eligible employees, and individuals who have contributed to the Group’s success;
- 33.93 million Issue Shares assigned to institutional and selected investors.
The Company received a total of 16,671 applications for 924,756,100 IssueShares, resulting in an oversubscription rate of 58.69 times. Within the Bumiputera category, TOPVISION garnered 8,210 applications for 381,749,700 Issue Shares, reflecting an oversubscription rate of 48.28 times. The public category attracted 8,461 applications for 543,006,400 Issue Shares, achieving an oversubscription rate of 69.10 times. Additionally, the interests to subscribe for the Issue Shares under the Institutional Offering was well received, further underlining the robust institutional interest in TOPVISION’s business model and growth outlook.
All 4.80 million Issue Shares allocated to eligible persons were fully subscribed.
Dr. Peter Chong Kuok Siong, Chief Executive Officer and Executive Director of TOPVISION shared, “We are deeply honoured by the response to our Public Offering and the confidence investors have shown in us. This support motivates us as we embark on this exciting next chapter. The proceeds will empower us to expand our service network and establish TOPVISION International, a multidisciplinary specialist tertiary eye ACC to better serve our patients.”
Datuk Kenny Liew Hock Nean, Executive Vice Chairman of TOPVISION, said, “The overwhelming demand for our Public Offering underscores the market’s trust in our vision and growth plans. We are immensely grateful for the unwavering support from our investors, partners, and stakeholders, and we remain committed to delivering exceptional, accessible eye care throughout Malaysia.”
Ms. Lee Jim Leng, Group Managing Director/ Chief Executive Officer of HLIB stated, “The good response from TOPVISION’s Public Offering reflects the market’s recognition of the Company’s strong foundation and strategic direction. TOPVISION is on track to make a meaningful impact in Malaysia’s healthcare sector, and we are proud to support their journey toward sustainable growth.”
Hong Leong Investment Bank Berhad is the Principal Adviser, Sponsor, Sole Underwriter and Sole Bookrunner.
TOPVISION Eye Specialist Berhad is scheduled to debut on the ACE Market of Bursa Malaysia Securities Berhad on 16 December 2024.
